Welcome to the First Annual Issue of HOPA Abstracts, 2021

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts
Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Director, Pharmacy Cancer Care, and Assistant Professor of Pharmacy, Mayo Clinic, Rochester, MN; HOPA Past President, 2016-2017

Welcome to the special issue of the Journal of Hematology Oncology Pharmacy (JHOP), the official publisher of the Hematology Oncology Pharmacy Association (HOPA). This special issue represents the First Annual Issue of HOPA Abstracts, 2021, and features a selection of the abstracts presented at the 17th Annual Conference of HOPA.

The abstracts featured in this issue were selected through a peer review by the HOPA Review Committee among the more than 300 abstracts that were presented at the 2021 HOPA Annual Conference on April 13-17, 2021. Because of the current pandemic restrictions, this year’s annual conference was held as a virtual meeting.

Formed in 2004, HOPA is a nonprofit, education-based organization created to help hematology oncology pharmacy practitioners and their associates to provide the best possible cancer care. HOPA’s 2004 mission statement was “to reduce the burden of cancer on society and promote optimal, cost-effective care for those affected by cancer.”

Today, HOPA supports hematology oncology research, provides education, encourages the professional development of hematology oncology pharmacists, and advocates for health policy issues that aim to improve patient care.

Currently totaling more than 3000 members, HOPA serves members in the fields of hematology oncology pharmacy, pharmacy administration, and research, and includes pharmacists, pharmacy residents, interns, and technicians specializing in hematology oncology practice.

HOPA’s mission is to support hematology oncology pharmacy practitioners and promote and advance hematology oncology pharmacy to optimize the care of individuals affected by cancer. The overarching goal of the organization is to ensure that every patient affected by cancer can have a hematology oncology pharmacist on their care team to optimize the medical care they receive.

The 20 abstracts featured in this special issue represent a sample of the hard work of pharmacists, researchers, residents, and pharmacy students in the United States and across the globe in the areas of clinical research, translational science, quality improvement, and practice management—all focused on the delivery of optimal care for the individual patient with cancer.

Related Items
Assessing Student Pharmacists’ Knowledge and Perceptions of Financial Toxicity Concepts Introduced in an Oncology Pharmacotherapy Course
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Biodistribution and Shedding Analysis Following RP1 Oncolytic Immunotherapy Dosing in Patients From the IGNYTE Clinical Trial: Implications for Oncology Pharmacists
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Characterizing Second-Line and Beyond Treatments for Primary Central Nervous System Lymphomas
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Coordinating Better Outcomes in Multiple Myeloma: An Educational Initiative to Elevate Pharmacist Leadership in Novel Antibodies and CAR-T Therapy
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients in the United States (DEAR): Comparative Real-World Evidence
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Dosing, Safety, and Pharmacokinetics of Combination Therapy With Darolutamide, Androgen-Deprivation Therapy, and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer in the ARASENS Study
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Evaluating Patient Hesitancy in Receiving a Second Dose of Evusheld (Tixagevimab and Cilgavimab) for COVID-19 Prevention After a Food and Drug Administration Dosing Recommendation Update
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
First-Line Nivolumab + Ipilimumab + Chemotherapy Versus Chemotherapy Alone in Metastatic Non–Small Cell Lung Cancer: CheckMate 9LA 4-Year Clinical Update
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Impact of Frailty on Outcomes After CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Improving Post-Transplant Vaccination Compliance via Implementation of a Clinical Pharmacist–Managed Service
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: